Objective:
AB-101 as Monotherapy
Primary Objectives:
- To evaluate the safety of AB-101 as monotherapy when administered to patients with relapsed/refractory (R/R) NHL of B-cell origin.
Secondary Objectives:
- To describe the clinical activity of AB-101 as monotherapy when administered to patients with R/R NHL of B-cell origin.
AB-101 Combination with Rituximab
Primary Objectives:
- To evaluate the safety and potential clinical activity of AB-101 in combination with rituximab when administered to patients with R/R NHL of B-cell origin. Identify the recommended Phase 2 dose (RP2D)
Secondary Objectives:
- To evaluate additional endpoints for clinical activity of AB-101 in combination with rituximab when administered to patients with R/R NHL of B-cell origin.
- AB-101 Combination with Rituximab – Phase 2
Primary Objectives:
- To determine the efficacy profile of AB-101 in combination with rituximab when administered to patients with R/R NHL of B-cell origin.
Secondary Objectives:
- To evaluate additional endpoints to determine the efficacy profile of AB-101 in combination with rituximab when administered to patients with R/R NHL of B-cell origin.
- To determine the safety profile of AB-101 in combination with rituximab when administered to patients with R/R NHL of B-cell origin.